IMPDH1P10: A Promising Drug Target / Biomarker (G100874399)

Target Name: IMPDH1P10

NCBI ID: G100874399

IMPDH1P10

Other Name(s): inosine monophosphate dehydrogenase 1 pseudogene 10 | Inosine monophosphate dehydrogenase 1 pseudogene 10

IMPDH1P10: A Promising Drug Target / Biomarker

IMPDH1P10 is a protein that is expressed in various tissues throughout the body. It is a key regulator of the inter-cellular signaling pathway known as the insulin-like growth factor (IGF) signaling pathway. This pathway plays a crucial role in the development, maintenance, and regulation of tissues, including muscles, bones, and organs. It is also involved in the regulation of cellular processes such as cell growth, differentiation, and survival.

The IMPDH1P10 protein has been identified as a potential drug target or biomarker for various diseases, including cancer, obesity, and neurodegenerative diseases. This is due to its involvement in the IGF signaling pathway, which is often disrupted in these conditions.

The IGF signaling pathway is a critical regulator of cellular processes that promote growth, differentiation, and survival. It is composed of several transcription factors, including SMAD1, SMAD4, and FGF1. These transcription factors bind to specific DNA sequences to regulate the expression of target genes, including IMPDH1P10.

IMPDH1P10 is a key regulator of the IGF signaling pathway. It is a 21-kDa protein that is expressed in various tissues, including muscle, liver, and brain. It is highly conserved and has a similar structure to other members of the IMPDH family, which includes IMPDH2 and IMPDH3.

IMPDH1P10 functions as a negative regulator of the IGF signaling pathway. It binds to the SMAD receptor, which is a transmembrane protein that is composed of two distinct subunits. This interaction between IMPDH1P10 and SMAD leads to the inhibition of SMAD2, which is the transcription factor that activates the IGF signaling pathway.

The IGF signaling pathway is involved in the regulation of cellular processes that are critical for human growth and development. It is involved in the development and maintenance of tissues, including muscles, bones, and organs. It is also involved in the regulation of cellular processes such as cell growth, differentiation, and survival.

IMPDH1P10 is a key regulator of the IGF signaling pathway. It is involved in the regulation of cellular processes that are critical for human growth and development. It is a potential drug target or biomarker for various diseases, including cancer, obesity, and neurodegenerative diseases.

Conclusion

IMPDH1P10 is a protein that is involved in the regulation of the IGF signaling pathway. It is a key regulator of this pathway and plays a crucial role in the development, maintenance, and regulation of tissues. It is also involved in the regulation of cellular processes such as cell growth, differentiation, and survival.

IMPDH1P10 is a potential drug target or biomarker for various diseases, including cancer, obesity, and neurodegenerative diseases. Its involvement in the IGF signaling pathway makes it an attractive target for the development of new treatments for these conditions. Further research is needed to fully understand the role of IMPDH1P10 in the regulation of IGF signaling and its potential as a drug target.

Protein Name: Inosine Monophosphate Dehydrogenase 1 Pseudogene 10

The "IMPDH1P10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IMPDH1P10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets